Structure-activity studies and therapeutic potential of host defense peptides of human thrombin

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2880-2890

  Kasetty, Gopinath ^a   Papareddy, Praveen ^a   Kalle, Martina ^a   Rydengård, Victoria ^a   Mörgelin, Matthias ^a   Albiger, Barbara ^a   Malmsten, Martin ^b   Schmidtchen, Artur ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FYT 20; GKY 20; GKY 25; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; POLYPEPTIDE ANTIBIOTIC AGENT; THROMBIN; UNCLASSIFIED DRUG; YTH 20; ZYMOSAN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; ESCHERICHIA COLI; GENE DELETION; HOST RESISTANCE; IMMUNOMODULATION; MACROPHAGE ACTIVATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 79956330145     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01515-10     Document Type: Article

References (48)

1. Blondelle, S. E., and K. Lohner. 2000. Combinatorial libraries: a tool to design antimicrobial and antifungal peptide analogues having lytic specificities for structure-activity relationship studies. Biopolymers 55:74-87.
2. Bode, W. 2006. The structure of thrombin: a janus-headed proteinase. Semin. Thromb. Hemost. 32(Suppl. 1):16-31.
3. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250.
4. Cole, A. M., et al. 2001. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J. Immunol. 167:623-627. (Pubitemid 32660811)
5. de Jong, H. K., T. van der Poll, and W. J. Wiersinga. 2010. The systemic pro-inflammatory response in sepsis. J. Innate Immun. 2:422-430.
6. Easton, D. M., A. Nijnik, M. L. Mayer, and R. E. Hancock. 2009. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol. 27:582-590.
7. Elsbach, P. 2003. What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses? J. Clin. Invest. 111:1643-1645.
8. Fernandez-Lopez, S., et al. 2001. Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature 412:452-455. (Pubitemid 32702711)
9. Fjell, C. D., H. Jenssen, W. A. Cheung, R. E. Hancock, and A. Cherkasov. 2011. Optimization of antibacterial peptides by genetic algorithms and cheminformatics. Chem. Biol. Drug Des. 77:48-56.
10. French, G. L. 2005. Clinical impact and relevance of antibiotic resistance. Adv. Drug Deliv. Rev. 57:1514-1527.
11. Frick, I. M., et al. 2006. The contact system - a novel branch of innate immunity generating antibacterial peptides. EMBO J. 25:5569-5578.
12. Ganz, T. 2003. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3:710-720.
13. Greenfield, N., and G. D. Fasman. 1969. Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry 8:4108-4116.
14. Hancock, R. E., and H. G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557.
15. Hilpert, K., R. Volkmer-Engert, T. Walter, and R. E. Hancock. 2005. High-throughput generation of small antibacterial peptides with improved activity. Nat. Biotechnol. 23:1008-1012.
16. Hirsch, T., F. Jacobsen, H. U. Steinau, and L. Steinstraesser. 2008. Host defense peptides and the new line of defence against multiresistant infections. Protein Pept. Lett. 15:238-243.
17. Jenssen, H., and R. E. Hancock. 2010. Therapeutic potential of HDPs as immunomodulatory agents. Methods Mol. Biol. 618:329-347.
18. Jenssen, H., et al. 2007. Evaluating different descriptors for model design of antimicrobial peptides with enhanced activity toward P. aeruginosa. Chem. Biol. Drug Des. 70:134-142. (Pubitemid 47228660)
19. Kowalska, K., D. B. Carr, and A. W. Lipkowski. 2002. Direct antimicrobial properties of substance P. Life Sci. 71:747-750.
20. Lehrer, R. I., M. Rosenman, S. S. Harwig, R. Jackson, and P. Eisenhauer. 1991. Ultrasensitive assays for endogenous antimicrobial polypeptides. J. Immunol. Methods 137:167-173.
21. Luo, P., and R. L. Baldwin. 2002. Origin of the different strengths of the (i,i+4) and (i,i+3) leucine pair interactions in helices. Biophys. Chem. 96:103-108.
22. Malmsten, M., et al. 2007. Antimicrobial peptides derived from growth factors. Growth Factors 25:60-70. (Pubitemid 46672287)
23. Malmsten, M., G. Kasetty, M. Pasupuleti, J. Alenfall, and A. Schmidtchen. 2011. Highly selective end-tagged antimicrobial peptides derived from PRELP. PLoS One 6:e16400.
24. Marr, A. K., W. J. Gooderham, and R. E. Hancock. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6:468-472.
25. Mookherjee, N., et al. 2006. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 176:2455-2464. (Pubitemid 43201696)
26. Mookherjee, N., et al. 2009. Intracellular receptor for human host defense peptide LL-37 in monocytes. J. Immunol. 183:2688-2696.
27. Mor, A., M. Amiche, and P. Nicolas. 1994. Structure, synthesis, and activity of dermaseptin b, a novel vertebrate defensive peptide from frog skin: relationship with adenoregulin. Biochemistry 33:6642-6650. (Pubitemid 24189379)
28. Nijnik, A., et al. 2010. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J. Immunol. 184:2539-2550.
29. Nordahl, E. A., V. Rydengård, M. Mörgelin, and A. Schmidtchen. 2005. Domain 5 of high molecular weight kininogen is antibacterial. J. Biol. Chem. 280:34832-34839.
30. Nordahl, E. A., et al. 2004. Activation of the complement system generates antibacterial peptides. Proc. Natl. Acad. Sci. U. S. A. 101:16879-16884.
31. Papareddy, P., et al. 2010. Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog. 6:e1000857.
32. Pasupuleti, M., A. Chalupka, M. Mörgelin, A. Schmidtchen, and M. Malmsten. 2009. Tryptophan end-tagging of antimicrobial peptides for increased potency against Pseudomonas aeruginosa. Biochim. Biophys. Acta 1790:800-808.
33. Pasupuleti, M., A. Schmidtchen, A. Chalupka, L. Ringstad, and M. Malmsten. 2009. End-tagging of ultra-short antimicrobial peptides by W/F stretches to facilitate bacterial killing. PLoS One 4:e5285.
34. Pasupuleti, M., et al. 2007. Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. J. Biol. Chem. 282:2520-2528.
35. Pasupuleti, M., B. Walse, B. Svensson, M. Malmsten, and A. Schmidtchen. 2008. Rational design of antimicrobial C3a analogues with enhanced effects against staphylococci using an integrated structure and function-based approach. Biochemistry 47:9057-9070.
36. Pollock, J. S., et al. 1991. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 88:10480-10484.
37. Ringstad, L., A. Schmidtchen, and M. Malmsten. 2006. Effect of peptide length on the interaction between consensus peptides and DOPC/DOPA bilayers. Langmuir 22:5042-5050. (Pubitemid 44012069)
38. Rosenfeld, Y., N. Papo, and Y. Shai. 2006. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J. Biol. Chem. 281:1636-1643.
39. Rydengård, V., E. Andersson Nordahl, and A. Schmidtchen. 2006. Zinc potentiates the antibacterial effects of histidine-rich peptides against Enterococcus faecalis. FEBS J. 273:2399-2406. (Pubitemid 43736654)
40. Sajjan, U. S., et al. 2001. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob. Agents Chemother. 45:3437-3444.
41. Schmidtchen, A., et al. 2009. Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J. Biol. Chem. 284:17584-17594.
42. Sjogren, H., and S. Ulvenlund. 2005. Comparison of the helix-coil transition of a titrating polypeptide in aqueous solutions and at the air-water interface. Biophys. Chem. 116:11-21.
43. Steinstraesser, L., U. Kraneburg, F. Jacobsen, and S. Al-Benna. 2011. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 216:322-333.
44. Taboureau, O., et al. 2006. Design of novispirin antimicrobial peptides by quantitative structure-activity relationship. Chem. Biol. Drug Des. 68:48-57.
45. van der Does, A. M., et al. 2010. LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J. Immunol. 185:1442-1449.
46. van der Poll, T., and J. C. Meijers. 2010. Systemic inflammatory response syndrome and compensatory anti-inflammatory response syndrome in sepsis. J. Innate Immun. 2:379-380.
47. Wiegand, I., K. Hilpert, and R. E. Hancock. 2008. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3:163-175.
48. Zanetti, M. 2004. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75:39-48.